Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance  by Bock, Allison M. et al.
Biol Blood Marrow Transplant 19 (2013) 102e108American Society for Blood
ASBMT
and Marrow TransplantationBacteremia in Blood or Marrow Transplantation Patients:
Clinical Risk Factors for Infection and Emerging Antibiotic
Resistance
Allison M. Bock 1, Qing Cao 2, Patricia Ferrieri 3, Jo-Anne H. Young 1,
Daniel J. Weisdorf 1,*
1Department of Medicine, University of Minnesota, Minneapolis, Minnesota
2Masonic Cancer Center, Biostatistics & Bioinformatics Core, University of Minnesota, Minneapolis, Minnesota
3Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MinnesotaArticle history:
Received 19 June 2012
Accepted 20 August 2012
Key Words:
Bacterial infections
Antibiotic resistance
Blood and marrow
transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint re
ment of Medicine, University of
Delaware Street SE, Minneapolis, M
E-mail address: weisd001@umn
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Bacterial infections continue to be a leading cause of mortality and morbidity in patients who undergo blood
and marrow transplantations (BMTs). The relative importance of different clinical features (donor type, graft
cell source, and conditioning regimen) on the incidence and timing of posttransplantation bacterial infections
is uncertain, but a detailed analysis could better guide prevention and therapy. We retrospectively analyzed
the incidence and risk factors for early bacterial infections, as well as patterns of antibiotic resistance. We
observed 613 bacteremic events among 349 of 834 patients who underwent BMT treated at the University of
Minnesota from 2005 to 2010 (cumulative incidence 42%; 95% conﬁdence interval [CI], 38-45). Donor type
(allogeneic vs autologous) had the greatest impact on the incidence of bacteremia within 100 days post-
transplantation. Among allogeneic transplantations, myeloablative (MA), compared to reduced-intensity
conditioning (RIC) was associated with a signiﬁcantly greater risk of bacteremia, as was the development of
acute graft-versus-host disease (aGVHD). Additionally, patients who underwent BMT, compared to the
contemporaneous hospital population, developed infections with more frequent resistance to antibiotics used
in the treatment against commonly isolated bacterial organisms. These ﬁndings have important clinical
implications regarding the use and selection of both prophylactic and empiric antibiotic regimens.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bacterial infections are common after blood and marrow
transplantations (BMTs) and are a major source of mortality
[1]. The ﬁrst 2 to 4 weeks after transplantation are charac-
terized by severe neutropenia (absolute neutrophil count
<500 cells/mL), which has long been recognized as a risk
factor for bacteremia [2-5]. Additional risks for bacterial
infection come from disruption of mucous membranes by
pretransplantation myeloablative (MA) conditioning,
breached portals of entry through central venous lines and
catheters, prolonged neutropenia, and from the added
immune compromise occurring in patients with graft-
versus-host disease (GVHD). GVHD occurs in 20% to 70% of
BMT recipients receiving grafts from different donor sources
[6-8] and has been associated with bacteremia [7]; although
quantifying the nature of that risk has been difﬁcult. GVHD
pathogenesis is associated with alloreactivity of donor T cells
targeting histocompatibility antigens, leading to a cytotoxic
and inﬂammatory response and damage to the epithelial,
epidermal, and lymphohematopoietic targets of GVHD [8].
Patient age, previous medical condition, as well as the graft
cell and donor source, along with tissue damage from the
conditioning regimen are all implicated in the development
of GVHD and its inﬂuence on host defenses [2]. Donor type
and conditioning regimen intensity may also inﬂuence the
incidence of bacteremia and subsequent infection. Althoughedgment on page 108.
quests: Daniel J. Weisdorf, MD, Depart-
Minnesota, Mayo Mail Code 480; 420
N 55455.
.edu (D.J. Weisdorf).
2013 American Society for Blood and Marrow
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graphics, the impact of donor source and GVHD on the risks
of bacterial infection, their incidence, and mortality have not
been recently reported.
During the initial pre-engraftment stage of trans-
plantation, most bacteria causing bloodstream infections
include normal skin and intestinal ﬂora such as coagulase-
negative Staphylococcus, Streptococcus, and Enterococcus
species, as well as Gram-negative bacilli [2], although inci-
dence trends vary signiﬁcantly between institutions.
Although less frequent, bacteremia has been observed after
neutrophil recovery and engraftment and may contribute to
later infection morbidity [1,6]. Infections by Gram-negative
organisms, which often have high rates of mortality, can
occur late after transplantation [6]. Common prophylactic
antibiotic regimens including the use of a quinolone, such as
levoﬂoxacin, broad-spectrum b-lactams, or other broad anti-
Gram-negative antibiotics have been found to reduce the
rate of Gram-negative infections, including P. aeruginosa
[9,10]. However, the growing concern of antibiotic resistance
complicates therapy options for empiric or therapeutic
antibiotic treatment of neutropenic fever or deﬁned bacterial
infection. Enterococcus species are inherently resistant to
quinolones, which are often used in prophylaxis treatments
[11]. This can facilitate the further development of resistance
and correspondingly, colonization and infection by
vancomycin-resistant enterococci, which are associated with
multidrug resistance and up to a 75% mortality rate [12].
Multidrug resistant Gram-negative species were docu-
mented to account for 37% of all Gram-negative isolates in 1
institution [12]. Several institutions have noted the ree-
mergence of Gram-negative bacteremia despite a switch toTransplantation.
Table 1
Clinical Features of Patients with and without Bacteremia
Features Patients without
Bacteremia by
Day 100; N (%)
Patients with
Bacteremia by
Day 100; N (%)
P
Value
All 485 (58) 349 (42)
Gender .11
Male 299 (62) 196 (56)
Female 186 (38) 153 (44)
Recipient age <.01
Median (range) 51 (18-74) 48 (18-74)
Diagnosis before BMT <.01
AA-idiopathic 2 (1) 5 (1)
AA–other 7 (1) 6 (2)
Hemoglobinopathy 1 (<1) 0
Metabolic disorder 8 (2) 1 (<1)
ALL 29 (6) 42 (12)
AML 102 (21) 116 (33)
CML 13 (3) 9 (3)
Other leukemia 14 (3) 9 (3)
MDS 24 (5) 32 (9)
Lymphoma (non-Hodgkin) 121 (25) 59 (17)
Lymphoma (Hodgkin) 49 (10) 16 (5)
Neuroblastoma 1 (<1) 1 (<1)
Myeloproliferative disorder 4 (1) 8 (2)
Other malignancy 109 (22) 45 (13)
Donor type <.01
Autologous (self) 213 (44) 66 (19)
Sibling 104 (21) 91 (26)
Non sibling RD 152 (31) 172 (49)
URD 16 (3) 20 (6)
UCB 134 (28) 152 (44)
Time to ANC engraftment <.01
Median (range) days 11 (0-42) 13 (0-42)
aGVHD grade II-IV 97 (20) 111 (32) <.01
aGVHD grade III-IV 39 (39) 54 (15) <.01
BMT indicates bonemarrow transplantation; AA, aplastic anemia; ALL, acute
lymphocytic leukemia; AML, acute myelogenous leukemia; CML, chronic
myelogenous leukemia; MDS, myelodysplastic syndrome; RD, related
donor; URD, unrelated donor; UCB, umbilical cord blood; ANC, absolute
neutrophil count >500/mL; aGVHD, acute graft-versus-host disease.
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emergence of added antibiotic resistance [9,13].
To deﬁne risk factors for bacterial infection, we studied
the type and incidence of bacteremia in patients who
underwent BMT from January 2005 to October 2010 at the
University of Minnesota Medical Center (UMMC) and
compared antibiotic sensitivity proﬁles of bloodstream
isolates from BMT recipients with the contemporaneous
hospital-wide bacterial ﬂora.METHODS
Patients and Deﬁnitions
All adults who underwent a BMT between January 1, 2005, and October
31, 2010, at the UMMC were included in this study. Patients were identiﬁed
from the University of Minnesota Blood and Marrow Transplant Program
database, which contains prospectively collected data on all patients
undergoing transplantation at the center and was supplemented by data
from the hospital microbiology laboratory. The study protocol was approved
by the University of Minnesota Institutional Review Board as were all the
treatment protocols in which the patients provided informed consent for
treatment as well as for long-term conﬁdential storage of their outcome
data.
The study cohort included all adult patients with at least 1 positive
bacterial blood culture within the ﬁrst 100 days posttransplantation. A
patient was identiﬁed as havingmore than 1 bacteremic event if the cultures
for the same bacterial isolate were at least 7 days apart. If the blood culture
was polymicrobial, each isolate was considered a bacteremic event. For
coagulase-negative Staphylococcus speciﬁcally, the ﬁrst blood isolate was
used for purposes of the analysis. If coagulase-negative Staphylococcus was
isolated in only 1 blood culture, but the episode was treated by the clinician
(one-third of coagulase-negative staphylococcal bloodstream infection
episodes), it was counted as a bacteremic event.Patients ranged in age from 18 to 74 years with a median age of 51 years.
The male-to-female ratio was approximately 1.5:1. The major diagnoses in
the transplantation population included acute myeloid and chronic
leukemia, myelodysplastic syndrome, and lymphoma (including Hodgkin
disease and non-Hodgkin) (Table 1). Allogeneic donor transplantation
recipients accepted stem cells from sibling or non sibling-related donors
(RDs), or unrelated donors (URDs) of either bone marrow/peripheral blood
stem cells or unrelated umbilical cord blood (UCB). Either MA or non-MA
(reduced-intensity conditioning [RIC]) was administered before trans-
plantation. All patients, during the period of the study, received a prophy-
lactic antibacterial antibiotic, generally levoﬂoxacin because of its broad
spectrum of action against Gram-positive and Gram-negative organisms [9].
If allergic, patients were given penicillin or a related b-lactam antibiotic. On
days 1 to 3 of neutropenic fever, initial empiric antibiotic therapy included
ceftazidime plus vancomycin for 48 hours (to cover coagulase-negative
Staphylococcus infection). Adult inpatients also received tobramycin while
reassessing clinical status each day to determine the need for its continued
use. For adult outpatients, tobramycin was often continued once daily for 3
days. Levoﬂoxacin was initially continued for coverage of organisms that
may be resistant to cephalosporins and aminoglycosides. This clinical
treatment algorithm did not change over the period of study. GVHD was
diagnosed and graded according to standard criteria [14,15].
Review of Patient Data
All patients with at least 1 bacteremic event during the ﬁrst 100 days
posttransplantation were considered to have bacteremia in the study. We
analyzed 3 subgroups of infections: any type of bacteremia, bacteremia
other than coagulase-negative Staphylococci, and Gram-negatives only. Risk
factors for these 3 infection subgroups were assessed overall and during the
ﬁrst 3 monthly intervals after transplantation. A polymicrobial infectionwas
deﬁned as 1 patient with 2 different bacterial organisms 3 days apart.
Polymicrobial and other infections were assessed overall, in 3 2-year
intervals (2005-2006, 2007-2008, and 2009-2010) and in the ﬁrst, second,
and third month after transplantation. Patients without bacteremia during
the 6-year period were deﬁned as controls. The antibiotic sensitivity proﬁles
of BMT and contemporaneous UMMC hospital-wide bacterial isolates were
compared in the 3 2-year intervals (2005-2006, 2007-2008, and 2009-
2010).
Blood Cultures and Antibiotic Sensitivity Testing
Antibiotic sensitivities were performed on the ﬁrst positive blood
culture isolate taken from a patient. Blood cultures were drawn from the
central line, generally only 1 set, using aerobic bottles only, because
anaerobic bacteremia is uncommon in this population. Antibiotic sensitiv-
ities were determined using the Vitek Automated Microbiology System
(bioMérieux) or a microdilution minimum inhibitory concentration proce-
dure in the microbiology laboratory at UMMC [16]. Organisms were re-
ported as sensitive, intermediate, or resistant depending on the unique
minimum inhibitory concentration values for each organism and antibiotic.
Criteria for susceptibility were followed according to the National
Committee for Clinical Laboratory Standards guidelines [17].
Statistical Analyses
Patients and transplantation characteristics between patients with or
without bacteremia were compared using chi-square or Fisher exact test for
categorical data and Wilcoxon rank-sum test for continuous data. The
cumulative incidence of the ﬁrst occurrence of an infection was estimated
with the Lin model [18]. Multivariate regression of recurrent event analysis
was performed using a Prentice, Williams, and Peterson Total Time Model
with Common Effects [19]. This type of analysis was performed for the 3
infection subgroups (all bacteremia, all excluding coagulase-negative
Staphylococcus, and Gram-negative only) in the different time intervals
and with acute GVHD (aGVHD) grade III-IV or II-IV as a time-dependent
variable. Other factors considered included conditioning regimen inten-
sity, gender, age 51, donor type, and graft cell source. Logistic regression
was used to compare antibiotic sensitivities between hospital-wide and
patients who underwent BMT. All statistical analyses were performed with
Statistical Analysis Systems statistical software version 9.2 (SAS Institute,
Inc., Cary, NC) with a P value .05 that was considered statistically
signiﬁcant.
RESULTS
Incidence of Bacteremia
In the 834 patients who underwent BMT, the cumulative
incidence of bacteremia by day-100 post-BMT was 42% (95%
conﬁdence interval [CI], 38-45). There were 613 bacteremic
events in 349 patients; the median time from the day of
Figure 1. Cumulative incidence of bacteremia by 100 days posttransplantation comparing autologous and allogeneic transplantations and different allogeneic donor
types. Three infection groups are shown (all bacteremia, all excluding coagulase-negative Staphylococcus, and Gram-negative bacteria) (left panels). Among allogeneic
transplantations, the incidence of bacteremia is similar in each infection group (right panels). Allo, allogeneic transplantation; Auto, autologous transplantation; RD,
related donor; URD, unrelated donor, blood, or marrow cell source; UCB, umbilical cord blood.
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(range, 1-100 days). In each time interval and over the whole
time period (0-100 days), Gram-positive bacteria were the
most frequently identiﬁed. Gram-positive organisms
accounted for 88% of bacteremia events in patients who
underwent BMT overall, with coagulase-negative Staphylo-
coccus infections comprising over half of the Gram-positive
isolates. The cumulative incidence of Gram-negative bacter-
emia was 7% (95% CI, 5-9). Other than coagulase-negative
Staphylococcus, incidence rates for individual Gram-positive
and Gram-negative species were similar across the 3 2-year
time intervals of study. The top 3 bacterial organisms for
autologous transplantation recipients were as follows:
coagulase-negative Staphylococcus (n ¼ 50), Enterococcus
species (n ¼ 5), and Corynebacterium nos (n ¼ 4). The top 3
bacterial organisms for allogeneic transplantation recipients
were coagulase-negative Staphylococcus (n ¼ 343), Entero-
coccus species (n ¼ 151), and Pseudomonas species (n ¼ 28).
The top 5 bacterial organisms to occur within the ﬁrst 30
days of transplantation were coagulase-negative Staphylo-
coccus (n ¼ 207 events), Enterococcus species (n ¼ 72),
a-hemolytic Streptococci (n ¼ 17), or all Streptococci species,
E. coli (n ¼ 11), and Pseudomonas species (n ¼ 9). The top 4
bacterial organisms to occur within days 31 to 100 post-
transplantationwere coagulase-negative Staphylococcus (n¼
186), Enterococcus species (n ¼ 84), Pseudomonas species
(n ¼ 22), and E. coli (n ¼ 7). Gram-negative infectionsincluding Pseudomonas, E. coli, and K. pneumoniae infections
were identiﬁed over all monthly intervals. The Gram-
negative infections that contributed to deaths included
Pseudomonas aeruginosa (n¼ 2), E. coli (n¼ 3), K. pneumoniae
(n ¼ 1), and Enterobacter cloacae (n ¼ 1). Infection was the
primary cause of death for 11% of patients overall (9 of 80
patients). Polymicrobial bacteremia occurred in 8% (95% CI,
6%-10%) of patients. The majority of polymicrobial events
involved coagulase-negative Staphylococcus, other Staphylo-
cocci, Streptococci, Enterococci, E. coli, and Pseudomonas
species isolates.
Compared to the ﬁrst month after transplantation, the
incidence of bacteremia was at least 40% lower in the
subsequent months, and this was apparent for all infection
subgroups (all bacteremia, all excluding coagulase-negative
Staphylococcus, and Gram-negative only). The incidence of
bacteremia was similar in the second and third months
posttransplantation for each of the 3 infection subgroups.
Bacteremia by any infection subgroup was signiﬁcantly more
frequent in recipients of allogeneic compared to autologous
transplantations (all P< .01) (Figure 1). Among the allogeneic
transplantations, a similar cumulative incidence was
observed for the different donor types (sibling, non sibling
RD, URD, and UCB) (Figure 1). For infection by any bacterial
species, patients receiving a transplantation from a non
sibling RD had the highest incidence of bacteremia, 54%
(37%-71%) compared to 47% (39%-54%) for patients receiving
Table 2
Multivariate Analysis: Donor Type and Acute GVHD Grade III-IV on Infection Risk
Allogeneic/Autologous aGVHD grade III-IV
Patient N* RRy (95% CI) P Value Relative Risky (95% CI) P Value
All bacteremias
Overall (0-100 days) 555/279 3.07 (2.30-4.11) <.01 1.77 (1.29-2.41) <.01
Month 1 (0-30) 555/279 2.09 (1.52-2.87) <.01 1.83 (.61-5.49) .28
Month 2 (31-60) 474/270 6.79 (3.32-13.9) <.01 1.5 (.95-2.38) .08
Month 3 (61-100) 427/262 59.95 (8.27-435) <.01 1.53 (0.99-2.36) .06
All bacteria excluding coagulase-negative Staphylococcus
Overall (0-100) 535/278 3.87 (2.53-5.93) <.01 1.89 (1.24-2.87) <.01
Month 1 (0-30) 535/278 2.85 (1.75-4.62) <.01 1.27 (.13-12.4) .84
Month 2 (31-60) 463/268 6.95 (2.59-18.7) <.01 1.73 (1.00-3.01) .05
Month 3 (61-100) 409/262 34.54 (4.75-251) <.01 1.41 (0.74-2.69) .30
aGVHD indicates acute graft-versus-host disease; RR, relative risk; CI, conﬁdence interval.
* Number of patients allogeneic/autologous.
y The RR compares allogeneic to the reference group of autologous and the relative risk of infection in patients with grade III-IV aGVHD compared to the
reference group of allogeneic recipients without grade III-IV aGVHD.
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dence). Patients with aGVHD grades II-IV or III-IV had
a higher incidence of bacteremia than patients without
GVHD (Table 1).
Risk Factors for Bacteremia
We then performed a risk factor analysis to examine the
effects of factors including gender, age, donor type, graft cell
source, conditioning regimen, and presence of GVHD on the
frequency of infection. Independent of other factors, in each
of the 3 infection groups, the donor source affected the
frequency of bacteremia. Among allogeneic transplantations,
MA conditioning and development of aGVHDwere identiﬁed
as risk factors for bacteremia, with similar trends between
the 3 infection subgroups.
Compared to autologous transplantations, allogeneic
transplantations had a 3.07 higher relative risk (RR), (95% CI,
2.30-4.11; P < .01) for bacteremia by any species within the
100-day period. The RR in the ﬁrst 30 days post-
transplantation was 2.09 (P < .01) compared to autologous
transplantations, an RR that increased to 6.79 in the secondTable 3
Multivariate Analysis: Conditioning Regimen and Donor Type on Risk and
Timing of Infection
Risk Factor Day 0-100 Day 0-30
RR (95% CI) P
Value
RR (95% CI) P
Value
All bacteremia
RIC* 1 1
MA 1.43 (1.13-1.80) <.01 1.70 (1.24-2.34) <.01
Sibling* 1 1
Non sibling RD 1.39 (0.90-2.14) .14 1.55 (0.85-2.82) .15
URD 1.22 (0.84-1.76) .30 1.17 (0.70-1.96) .55
UCB 1.22 (0.98-1.53) .08 1.19 (0.88-1.61) .26
GVHD III-IV 1.57 (1.15-2.15) <.01 1.54 (0.51-4.70) .44
All bacteria excluding
coagulase-negative
Staphylococcus
RIC* 1 1
MA 1.48 (1.08-2.01) .01 1.83 (1.16-2.87) <.01
Sibling* 1 1
Non sibling RD 1.74 (1.00-3.02) .05 2.08 (0.98-4.42) .06
URD 1.26 (0.73-2.16) .41 1.28 (0.58-2.81) .55
UCB 1.39 (1.01-1.90) .04 1.62 (1.05-2.52) .03
GVHD III-IV 1.69 (1.11-2.59) .02 0.91 (0.09-9.22) .94
RR indicates relative risk; CI, conﬁdence interval; RIC, reduced-intensity
conditioning; MA, myeloablative; RD, related donor; URD, unrelated donor;
UCB, umbilical cord blood; GVHD, graft-versus-host disease.
* Reference group.month (95% CI, 3.32-13.9; P < .01) and 59.95 in the third
month (95% CI, 8.27-435; P < .01) (Table 2), as the incidence
of later bacteremia in autologous recipients was very low. A
similar trend was apparent for bacteremia excluding
coagulase-negative Staphylococcus and for Gram-negative
bacteremia. The development of aGVHD grade III-IV was
a signiﬁcant risk factor for all bacteremia and bacteremia
excluding coagulase-negative Staphylococcus overall (0-100
days) with a modestly increased risk for infection sustained
in each of the ﬁrst 3 months posttransplantation. There was
a similar, but not statistically signiﬁcant increased risk for
Gram-negative bacteremiawith GVHD (data not shown). The
low incidence of Gram-negative bacteremia precluded
a useful analysis of infection risk within each of the 3 post-
transplantation months.
Among allogeneic transplantations only, we examined
conditioning intensity and the development of aGVHD after
transplantation for risks of bacteremia. For infection by any
bacterial species, MA conditioning was associated with a 1.43
higher RR (95% CI, 1.13-1.80; P < .01) overall and 1.70 higher
risk (95% CI, 1.24-2.34; P < .01) within the ﬁrst month
compared to RIC (Table 3). The development of aGVHD grade
III-IV was a signiﬁcant risk factor overall and in the third
month posttransplantation (P< .01 and P< .05, respectively),
with an increased, but nonsigniﬁcant risk in the ﬁrst and
second months posttransplantation. For all bacteremias,
no signiﬁcant risk was identiﬁed for donor type in
comparison to a sibling donor overall or within the 3 months
posttransplantation. For bacteremia excluding coagulase-
negative Staphylococcus, MA conditioning was also a signiﬁ-
cant risk factor both overall (1.48; 95% CI, 1.08-2.01) and in
the ﬁrst month (1.83; 95% CI, 1.16-2.87) (Table 3). Any aGVHD
grade III-IV presented a signiﬁcant risk overall (1.69; 95% CI,
1.11-2.59; P < .02) and in the second month (1.74; 95% CI,
1.01-3.01; P ¼ .05) after transplantation. For infections
excluding coagulase-negative Staphylococcus, patients
receiving a transplantation from a non sibling RD or UCB
were at signiﬁcantly higher risk (RR 1.74 and 1.39, respec-
tively) for developing infections compared to a sibling donor
overall, with the RR for UCB highest in the ﬁrst month (2.08;
95% CI, 0.98-4.42). No signiﬁcant risk was associated with
URD. The inﬂuence of conditioning regimen, development of
aGVHD grade III-IV, and allogeneic donor type on the risk of
bacteremia was less apparent for Gram-negative infections,
although a similar trend was present. There were no signif-
icant differences in risk of bacteremia based on gender or age
in any of the infection subgroups.
Figure 2. The in vitro antibiotic sensitivity of P. aeruginosa (A), E. coli (B), and
K. pneumoniae (C) blood isolates from hospital-wide patients and patients who
underwent BMT between 2005 and 2010. Diamond (A) denotes statistically
signiﬁcant sensitivity differences (P < .05) between hospital and bone marrow
transplantation (BMT) blood isolates.
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Patterns of antibiotic resistance to commonly used
antibiotics were assessed by examining in vitro antibiotic
sensitivity proﬁles during 3 2-year intervals (2005-2006,
2007-2008, and 2009-2010) and compared to the sensitiv-
ities in the general hospital population.
P. aeruginosa, E. coli, and K. pneumoniae accounted for the
majority of Gram-negative isolates within the BMT pop-
ulation. High rates of Pseudomonas resistance were observed
against gentamicin (>40%), levoﬂoxacin (>30%), and cefta-
zidime (>30%) with statistically signiﬁcant differences in
resistance between BMT and hospital isolates for cefotaxime
(P ¼ .02 in 2007-2008), ceftazidime (P ¼ .02 in 2005-2006
and 2007-2008), and gentamicin (P < .01 in 2005-2006; P ¼
.02 in 2007-2008 and 2009-2010), as shown in Figure 2A.
Tobramycinwas the only antibiotic showing <20% resistance
in the BMT population bacteremia isolates, with similarsensitivity rates in the BMT and hospital-wide populations.
For 4 of the 5 antibiotics tested (except gentamicin),
P. aeruginosa showed similar resistance incidence in isolates
from patients who underwent BMT during each of the 3
2-year intervals (2005-2006, 2007-2008, and 2009-2010);
thus, no substantive increasing rates of antibiotic resistance
were noted.
A similar trend was observed in the 6 antibiotics tested
against E. coli (Figure 2B). In the BMT population, E. coli
showed the greatest resistance to ampicillin (>50%), ampi-
cillin/sulbactam (>50%), and levoﬂoxacin (>60%), with
much more frequent resistance in patients who underwent
BMT than in isolates from the hospital population for
ampicillin (P ¼ .03 in 2009-2010), ampicillin/sulbactam (P ¼
.02 in 2005-2006; P ¼ .01 in 2007-2008), ceftazidime (P ¼
.03 in 2007-2008; P ¼ .01 in 2009-2010), levoﬂoxacin (P <
.01 for all), and piperacillin/tazobactam (P ¼ .02 in 2009-
2010) (Figure 2B). In the hospital, E. coli showed no evolving
drug resistance, but in BMT blood isolates, progressively
more frequent resistance to ampicillin (>70%) was noted
over time. When the E. coli antibiotic sensitivities were
compared independently in each month after trans-
plantation, all E. coli blood isolates were resistant to levo-
ﬂoxacin by the third month posttransplantation. Other than
continuing resistance to ampicillin (>40%), hospital E. coli
remained highly sensitive to each of the 5 antibiotics during
the 6 years of study.
In BMT patient isolates only, K. pneumoniae exhibited
>25% resistance to ceftazidime in each of the 3 2-year
intervals that was statistically different from hospital
isolates in 2007-2008 and 2009-2010 (P ¼ .03 for both)
(Figure 2C). Resistance to levoﬂoxacin increased from 0% to
>25% over the latter 4 years in patients who underwent
BMT. Hospital isolates remained highly sensitive to ceftazi-
dime, ceftriaxone, and levoﬂoxacin across the 6 years
of the study. Both BMT and general hospital population
K. pneumoniae isolates remained sensitive to ampicillin,
piperacillin/tazobactam, and tobramycin across the 6 years of
the study (Figure 2C).
For coagulase-negative Staphylococcus, the most
frequently isolated Gram-positive organism, patients who
underwent BMT showed >90% resistance to levoﬂoxacin
across the 6 years (Figure 3A). Coagulase-negative Staphylo-
coccus resistance to gentamicin in the BMT population
changed from w50% in 2005-2006 to 39% in 2007-2008
and 2009-2010, whereas resistance in hospital coagulase-
negative Staphylococcus isolates ranged between 26% and
36%. In each 2-year time interval, somewhat more frequent
resistance to gentamicin (P < .01 in 2005-2006, 2007-2008)
and levoﬂoxacin (P < .01 for all) was seen in the BMT pop-
ulation compared to the general hospital population
(Figure 3A). Among 393 BMT and 10,696 hospital coagulase-
negative Staphylococcus isolates, in vitro sensitivity to van-
comycin was universal in both the BMT and hospital pop-
ulations across the 6 years examined.
For Enteroccocus species (E. faecium and group D Entero-
coccus), BMT isolates showed 69% or greater resistance to the
3 antibiotics tested (ampicillin, levoﬂoxacin, and vancomy-
cin) (Figure 3B). Resistance to ampicillin in the BMT pop-
ulation increased slightly from 80% in 2005-2006 and
2007-2008 to 85% in 2009-2010. Enterococcus isolates
exhibited >90% resistance to levoﬂoxacin in the BMT pop-
ulation across the 6 years. Vancomycin resistance in the BMT
population was 75% in 2005-2006, 69% in 2007-2008, and
81% in 2009-2010. Other than showing frequent resistance to
Figure 3. The in vitro antibiotic sensitivity of coagulase-negative Staphylo-
coccus (coagulase-negative Staphylococcus) (A) and Enterococcus (including
E. faecium and group D Enterococcus) (B) blood isolates from hospital-wide
patients and patients who underwent bone marrow transplantation (BMT)
between 2005 and 2010. Diamond (A) denotes statistically signiﬁcant sensi-
tivity differences (P < .05) between hospital and BMT blood isolates
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to ampicillin (>80%) and vancomycin (>85%) within each
2-year time interval. Compared to the general hospital pop-
ulation, BMT patient isolates exhibited >40% resistance to
the 3 antibiotics tested in each 2-year interval (P< .01 for all).DISCUSSION
Successful management of infections is important for
timely recovery and patient well-being after transplantation.
This analysis shows the importance of several clinical factors,
with patients receiving allogeneic transplantations, espe-
cially those receiving MA conditioning regimens and those
developing aGVHD, to be at substantially greater risk for
bacteremia. A comparison of hospital-wide and BMT antibi-
otic sensitivities revealed greater resistance to levoﬂoxacin,
used as a prophylactic antibiotic, among isolates of E. coli,
P. aeruginosa, K. pneumonia, coagulase-negative Staphylo-
coccus, and Enterococcus species from patients who under-
went BMT. Drug resistance was frequent for these 3 main
Gram-negative and Enterococcus isolates from patients who
underwent BMT.
These antibiotic sensitivity proﬁles suggest that ceftazi-
dime alone is not adequate as empiric therapy for
P. aeruginosa, E. coli, or K. pneumoniae. Over the past 6 years,
antibiotic resistance in BMT blood isolates has become more
frequent; whereas in the general hospital population, nosimilar pattern was noted. For P. aeruginosa, either levo-
ﬂoxacin or gentamicin is also insufﬁcient as empiric therapy
when administered alone. Ampicillin, with or without sul-
bactam, and levoﬂoxacin do not provide adequate coverage
against infections by E. coli. These data emphasize the need
for continued institutional surveillance and inclusion of
tobramycin or other aminoglycosides as initial empiric
therapy.
Autologous transplantation using either a marrow or
peripheral blood graft was associated with the lowest
incidence of bacteremia, in agreement with earlier reports
[1,6,20]. These results conﬁrm that allogeneic trans-
plantations are associated with a much higher risk of
bacteremia compared to autologous transplantations; a risk
that is sustained during the ﬁrst 3 months after trans-
plantation. Among allogeneic transplantations, patients
receiving transplantation from a non sibling RD or URD had
the highest incidence of infection, which interestingly, was
similar for the 2 groups. Furthermore, there is a similar risk of
infection among the different types of allogeneic trans-
plantations and only a slightly lower risk of bacteremia in
transplantations from a sibling donor.
These analyses showed a concordance of risk for both
Gram-negative and Gram-positive organisms. We identiﬁed
no clinical factors associated with a different risk of Gram-
negative bacteremia, although our analysis was limited by
the lower incidence of Gram-negative infections. The
incidence of aGVHD grade III-IV was a signiﬁcant risk factor
for all bacteremias and for the noncoagulase-negative
Staphylococcus subgroups and suggestive for Gram-negative
organisms. The observed 42% incidence of bacteremia
in this high-risk BMT population was similar to earlier
reports, which ranged from 20% to 62% [6,20,21]. Most
infections were Gram-positive, most frequently coagulase-
negative Staphylococcus, as noted in some earlier literature
[1,12,21]. Infections by Gram-negative organisms repre-
sented a small subset of the population, yet the incidence of
the 3 main Gram-negative species (E. coli, P. aeruginosa,
and K. pneumoniae) was similar to the incidence of
many noncoagulase-negative Staphylococcus, Gram-positive
species. Gram-negative organisms have been associated
with more serious clinical consequences and complications
such as sepsis, pneumonia, and shock, and importantly, with
a higher case-fatality rate, likely because of the greater
inﬂammatory response triggered by endotoxemia [6,22-24].
Although the greatest incidence of bacteremia occurred
during the ﬁrst month posttransplantation, there was
a persistence of infection risk during the second and third
months, particularly for organisms other than coagulase-
negative Staphylococcus. The current clinical approaches for
antibiotic prophylaxis focus on the early neutropenic period,
but these later risks of bacteremia emphasize the need for
continued institutional surveillance of trends in antibiotic
resistance and perhaps antibiotic regimens differently
tailored to control these later infections.
Successful management of infection in patients who
undergo BMT also requires the prescription of effective
antibiotic regimens. Levoﬂoxacin is still widely used in this
transplantation population for prophylaxis, as levoﬂoxacin
(or other quinolones) have been associated with decreased
rates of Gram-negative bacteremia and rates of fever
[20,25]. Although some reports evaluating antibiotic resis-
tance associated with levoﬂoxacin prophylaxis identiﬁed no
emerging resistance [9,21], others have observed signiﬁcant
resistance to the prophylactic antibiotic used, which may
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[8,12]. Empiric antibiotic regimens are also crucial for
managing infection because initial antibiotic therapy, which
lacks coverage against the infecting organism, has been
associated with increasing mortality in patients with Gram-
negative bacteremia [26]. Appropriate initial therapy for
patients with sepsis due to Gram-negative bacteria yields
a lower likelihood of sepsis-related mortality [27]. This study
identiﬁed several antibiotics for E. coli, P. aeruginosa, and
K. pneumoniae that in our institution are insufﬁcient as
empiric therapy when administered alone, suggesting the
importance of combination empiric therapy, particularly
inclusion of tobramycin or other aminoglycosides as initial
empiric therapy for this high-risk population.
In comparison to the general hospital population, bacte-
rial isolates from patients who underwent BMT had a lower
sensitivity to almost all of the antibiotics tested across the 6
years of the study. With a few exceptions, the resistance did
not worsen over the 6-year time period. Reemergence of
infection and resistance by Gram-negative species has been
observed in other recent studies [12,28]. Prophylaxis or
broad use of third-generation cephalosporins has been
associated with the development of multidrug-resistant
Gram-negative isolates [11,12]. Other than Klebsiella resis-
tance to levoﬂoxacin showing an increase over the 6 years of
study, and similarly, E. coli resistance to ceftazidime, there
have not been other signiﬁcant resistance increases evolving
over the time period examined. The resistance patterns were
generally established by 2005-2006. However, altering
empiric antibiotic regimens based on resistance patterns
may be valuable for both effective prevention and therapy as
well as to halt further development of resistant ﬂora.
Effective preventionand treatmentof infections inpatients
who undergo BMT requires an accurate knowledge of bacte-
rial incidence and relative importance of clinical risk factors in
a given population and institution, as well as patterns of
antibiotic resistance. There are many factors to consider, and
the relationships between different clinical features is often
complex and situation-dependent. The results of this study
have shown the importance in distinguishing BMT antibiotic
resistance trends from hospital-wide trends. This distinction
is important to consider when deciding on the prescription of
prophylaxis and empiric antibiotic regimens, guided by an
institutional population’s experience.
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